Targeting Aurora Kinases in Cancer Treatment

Author(s): Kevin R. Kelly, Jeffrey Ecsedy, Devalingam Mahalingam, Steffan T. Nawrocki, Swaminathan Padmanabhan, Francis J. Giles, Jennifer S. Carew

Journal Name: Current Drug Targets

Volume 12 , Issue 14 , 2011

Become EABM
Become Reviewer


The Aurora family of serine/threonine kinases is essential for chromosome alignment, segregation, centrosomal maturation, mitotic spindle formation, and cytokinesis during mitosis. Their fundamental role in cell cycle regulation and aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Recent studies have revealed new insights into the cellular effects of Aurora kinase inhibition. Moreover, early phase clinical studies have shown that these agents have therapeutic efficacy. In this review, we will outline the functions of Aurora kinases in normal cell division and in malignancy. We will focus on recent preclinical and clinical studies that have explored the mechanism of action and clinical effect of Aurora inhibitors in cancer treatment.

Keywords: Aurora kinase inhibitors, cancer, tageted therapy, mitosis, clinical studies, cell cycle regulation, malignancy, Hesperadin, ZM447439, AT9283

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [2067 - 2078]
Pages: 12
DOI: 10.2174/138945011798829410
Price: $65

Article Metrics

PDF: 20